Taytulla is a drug owned by Allergan Pharmaceuticals International Ltd. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 29, 2020. Details of Taytulla's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US6652880 | Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants |
Mar, 2020
(4 years ago) |
Expired
|
| US5552394 | Low dose oral contraceptives with less breakthrough bleeding and sustained efficacy |
Jul, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Taytulla's patents.
Latest Legal Activities on Taytulla's Patents
Given below is the list of recent legal activities going on the following patents of Taytulla.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| File Marked Found | 05 Apr, 2017 | US6652880 |
| Recordation of Patent Grant Mailed Critical | 25 Nov, 2003 | US6652880 |
| Patent Issue Date Used in PTA Calculation Critical | 25 Nov, 2003 | US6652880 |
| Issue Notification Mailed Critical | 06 Nov, 2003 | US6652880 |
| Receipt into Pubs | 16 Oct, 2003 | US6652880 |
| Application Is Considered Ready for Issue Critical | 13 Oct, 2003 | US6652880 |
| Receipt into Pubs | 01 Oct, 2003 | US6652880 |
| Issue Fee Payment Received Critical | 25 Aug, 2003 | US6652880 |
| Issue Fee Payment Verified Critical | 25 Aug, 2003 | US6652880 |
| Receipt into Pubs | 18 Aug, 2003 | US6652880 |
US patents provide insights into the exclusivity only within the United States, but Taytulla is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Taytulla's family patents as well as insights into ongoing legal events on those patents.
Taytulla's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Taytulla's generic launch date based on the expiry of its last outstanding patent is estimated to be Mar 29, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Taytulla Generic API suppliers:
Ethinyl Estradiol; Norethindrone Acetate is the generic name for the brand Taytulla. 15 different companies have already filed for the generic of Taytulla, with Xiromed having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Taytulla's generic
Alternative Brands for Taytulla
Taytulla which is used for contraception., has several other brand drugs in the same treatment category and using the same active ingredient (Ethinyl Estradiol; Norethindrone Acetate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apil |
| |||||||||||
| Bayer Hlthcare |
| |||||||||||
| Evofem Inc |
| |||||||||||
| Organon |
| |||||||||||
| Teva Branded Pharm |
| |||||||||||
| Wyeth Pharms Inc |
| |||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Ethinyl Estradiol; Norethindrone Acetate. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Apil |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Ethinyl Estradiol; Norethindrone Acetate, Taytulla's active ingredient. Check the complete list of approved generic manufacturers for Taytulla
About Taytulla
Taytulla is a drug owned by Allergan Pharmaceuticals International Ltd. It is used for contraception. Taytulla uses Ethinyl Estradiol; Norethindrone Acetate as an active ingredient. Taytulla was launched by Apil in 2013.
Approval Date:
Taytulla was approved by FDA for market use on 19 April, 2013.
Active Ingredient:
Taytulla uses Ethinyl Estradiol; Norethindrone Acetate as the active ingredient. Check out other Drugs and Companies using Ethinyl Estradiol; Norethindrone Acetate ingredient
Treatment:
Taytulla is used for contraception.
Dosage:
Taytulla is available in capsule form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.02MG;1MG | CAPSULE | Prescription | ORAL |